首页> 美国卫生研究院文献>Chronic Respiratory Disease >Device use errors with soft mist inhalers: A global systematic literature review and meta-analysis
【2h】

Device use errors with soft mist inhalers: A global systematic literature review and meta-analysis

机译:软雾吸入器的设备使用错误:全球系统文献回顾和荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Inhaled bronchodilators are the cornerstone of treatment for chronic obstructive pulmonary disease (COPD). Soft mist inhalers (SMIs) are devices that deliver bronchodilators. Although correct device use is paramount to successful medication delivery, patient errors are common. This global systematic literature review and meta-analysis examined device use errors with SMIs among patients with obstructive lung diseases. PubMed, EMBASE, PsycINFO, Cochrane, and Google Scholar were searched to identify studies published between 2010 and 2019 that met the following inclusion criteria: (a) English language; (b) a diagnosis of COPD, bronchitis, or emphysema; and (c) reported device use errors among adults receiving long-acting bronchodilator treatment with Respimat® SMI (i.e. Spiriva®, Stiolto®, Spiolto®, and Striverdi®). Descriptive statistics examined sociodemographics, clinical characteristics, and device use errors. Meta-analysis techniques were employed with random-effects models to generate pooled mean effect sizes and 95% confidence intervals (CIs) for overall and step-by-step errors. The statistic measured heterogeneity. Twelve studies ( = 1288 patients) were included in this meta-analysis. Eighty-eight percent of patients had COPD, and most had moderate/very severe airflow limitation (Global Initiative for Chronic Obstructive Lung Disease spirometric stages II to IV). Aggregate results revealed that 58.9% (95% CI: 42.4–75.5; = 92.8%) of patients made ≥1 device use errors. Among 11 studies with step-by-step data, the most common errors were failure to (1) exhale completely and away from the device (47.8% (95% CI: 33.6–62.0)); (2) hold breath for up to 10 seconds (30.6% (95% CI: 17.5–43.7)); (3) take a slow, deep breath while pressing the dose release button (27.9% (95% CI: 14.5–41.2)); (4) hold the inhaler upright (22.6% (95% CI: 6.2–39.0)); and (5) turn the base toward the arrows until it clicked (17.6% (95% CI: 3.0–32.2)). Device use errors occurred in about 6 of 10 patients who used SMIs. An individualized approach to inhalation device selection and ongoing training and monitoring of device use are important in optimizing bronchodilator treatment.
机译:吸入支气管扩张剂是治疗慢性阻塞性肺疾病(COPD)的基础。软雾吸入器(SMI)是输送支气管扩张剂的设备。尽管正确使用设备对成功输送药物至关重要,但患者失误是常见的。这项全球系统的文献综述和荟萃分析检查了阻塞性肺疾病患者中SMI的设备使用错误。搜索PubMed,EMBASE,PsycINFO,Cochrane和Google Scholar,以识别2010年至2019年之间发表的符合以下纳入标准的研究:(a)英语; (b)诊断为COPD,支气管炎或肺气肿; (c)报告了接受长效支气管扩张剂用Respimat®SMI(即Spiriva®,Stiolto®,Spiolto®和Striverdi®)治疗的成年人使用器械的错误。描述性统计检查了社会人口统计学,临床特征和设备使用错误。荟萃分析技术与随机效应模型一起使用,以产生合并的平均效应大小和95%的置信区间(CI),用于总体误差和逐步误差。的 统计测得的异质性。这项荟萃分析包括十二项研究(= 1288例患者)。 88%的患者患有COPD,并且大多数患者有中度/非常严重的气流受限(全球慢性阻塞性肺疾病倡议肺量计II至IV期)。总体结果显示,该比率为58.9%(95%CI:42.4-75.5; = 92.8%)≥1个设备使用错误的患者。在11项具有逐步数据的研究中,最常见的错误是(1)无法完全呼出并远离设备(47.8%(95%CI:33.6-62.0))。 (2)屏住呼吸最多10秒钟(30.6%(95%CI:17.5-43.7)); (3)按下剂量释放按钮时要缓慢,深呼吸(27.9%(95%CI:14.5–41.2)); (4)保持吸入器直立(22.6%(95%CI:6.2-39.0)); (5)朝箭头方向旋转底座,直到其发出喀哒声为止(17.6%(95%CI:3.0-32.2))。在使用SMI的10名患者中,约有6名发生了设备使用错误。个性化的吸入装置选择方法以及对装置使用情况的持续培训和监视对于优化支气管扩张剂治疗很重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号